Piper Sandler analyst David Westenberg initiated coverage of Tempus AI with a Neutral rating and $40 price target. Tempus AI represents “the core idealism in personalized medicine,” to use deep genomic data to solve the most complex problem in diagnostics selection, the analyst tells investors in a research note. However, the firm we’re modeling on the lower end of Street estimates, and it would like to see the company generate more revenue in its artificial intelligence business before giving it the top industry multiple.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Cathie Wood’s ARK Investment bought 39.8K shares of Tempus AI today
- Cathie Wood’s ARK Investment bought 305K shares of Tempus AI today
- Tempus AI Issues Q2 2024 Financial Update and CEO Letter
- Tempus AI sees FY24 revenue roughly $700M, consensus $693.52M
- Tempus AI reports Q2 EPS ($6.86) vs ($1.07) last year